UCB S.A.
UCB
Κατάταξη σε μετοχές
#494
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Τιμή μετοχής
$258.70
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$49.32B
Αλλαγή (1 ημέρα)
6.29%
Αλλαγή (1 έτος)
-12.78%
Χώρα
BE
Εμπόριο UCB S.A. (UCB)
Κατηγορία
Healthcare
Έσοδα για την UCB S.A. (UCB)
Έσοδα τον Jun 2026 TTM: $10.11B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της UCB S.A., τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $10.11B. Το 2023, η εταιρεία είχε έσοδα $5.81B μείωση σε σύγκριση με τα έσοδα του έτους 2022, τα οποία ήταν $5.92B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την UCB S.A. από 2002 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $10.11B | 57.94% |
| 2024 | $6.40B | 10.26% |
| 2023 | $5.81B | -1.89% |
| 2022 | $5.92B | -9.92% |
| 2021 | $6.57B | 0.88% |
| 2020 | $6.51B | 18.13% |
| 2019 | $5.51B | 3.56% |
| 2018 | $5.32B | -0.85% |
| 2017 | $5.37B | 23.03% |
| 2016 | $4.36B | 3.68% |
| 2015 | $4.21B | 4.02% |
| 2014 | $4.05B | -6.09% |
| 2013 | $4.31B | -5.66% |
| 2012 | $4.57B | 8.68% |
| 2011 | $4.20B | -2.33% |
| 2010 | $4.30B | -3.70% |
| 2009 | $4.47B | -10.97% |
| 2008 | $5.02B | -5.32% |
| 2007 | $5.30B | 59.66% |
| 2006 | $3.32B | 20.02% |
| 2005 | $2.77B | -42.28% |
| 2004 | $4.79B | 14.36% |
| 2003 | $4.19B | -29.19% |
| 2002 | $5.92B | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $12.62B | 24.86% |
US
|
|
| $2.23B | -77.96% |
US
|
|
| $15.74B | 55.72% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | -40.45% |
NL
|
